Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

p28-Mediated Activation of p53 in G2-M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy.

Yamada T, Das Gupta TK, Beattie CW.

Cancer Res. 2016 Apr 15;76(8):2354-65. doi: 10.1158/0008-5472.CAN-15-2355. Epub 2016 Feb 26.

2.

p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation.

Yamada T, Das Gupta TK, Beattie CW.

Mol Pharm. 2013 Sep 3;10(9):3375-83. doi: 10.1021/mp400221r. Epub 2013 Aug 16.

PMID:
23952735
3.

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.

Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS.

PLoS One. 2013;8(2):e56817. doi: 10.1371/journal.pone.0056817. Epub 2013 Feb 15.

4.

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.

Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler L, Yamada T, Majumdar D, Kennedy SA, Beattie CW, Das Gupta TK.

Br J Cancer. 2013 Mar 19;108(5):1061-70. doi: 10.1038/bjc.2013.74. Epub 2013 Feb 28.

5.

A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.

Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D, Lekmine F, Tiruppathi C, Shilkaitis A, Bratescu L, Green A, Beattie CW, Das Gupta TK.

Angiogenesis. 2011 Sep;14(3):355-69. doi: 10.1007/s10456-011-9220-6. Epub 2011 Jun 11.

PMID:
21667138
6.

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.

Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, Harder JB, Muzzio M, Prabhakar B, Ganesh B, Das Gupta TK, Beattie CW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):513-24. doi: 10.1007/s00280-010-1518-3. Epub 2010 Nov 18.

PMID:
21085965
7.

A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.

Mehta RR, Hawthorne M, Peng X, Shilkaitis A, Mehta RG, Beattie CW, Das Gupta TK.

Cancer Prev Res (Phila). 2010 Oct;3(10):1351-60. doi: 10.1158/1940-6207.CAPR-10-0024. Epub 2010 Sep 14.

8.

A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells.

Yamada T, Mehta RR, Lekmine F, Christov K, King ML, Majumdar D, Shilkaitis A, Green A, Bratescu L, Beattie CW, Das Gupta TK.

Mol Cancer Ther. 2009 Oct;8(10):2947-58. doi: 10.1158/1535-7163.MCT-09-0444. Epub 2009 Oct 6.

9.

Bacterial proteins as potential drugs in the treatment of leukemia.

Kwan JM, Fialho AM, Kundu M, Thomas J, Hong CS, Das Gupta TK, Chakrabarty AM.

Leuk Res. 2009 Oct;33(10):1392-9. doi: 10.1016/j.leukres.2009.01.024. Epub 2009 Feb 27.

PMID:
19250673
10.

Noncationic peptides obtained from azurin preferentially enter cancer cells.

Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, Green A, Bratescu L, Shilkaitis A, Beattie CW, Das Gupta TK.

Cancer Res. 2009 Jan 15;69(2):537-46. doi: 10.1158/0008-5472.CAN-08-2932.

11.

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE.

J Clin Oncol. 2007 May 20;25(15):2078-85.

PMID:
17513813
12.

Beyond host-pathogen interactions: microbial defense strategy in the host environment.

Fialho AM, Stevens FJ, Das Gupta TK, Chakrabarty AM.

Curr Opin Biotechnol. 2007 Jun;18(3):279-86. Epub 2007 Apr 23. Review.

PMID:
17451932
13.

Role of microphthalmia transcription factor (Mitf) in melanoma differentiation.

Lekmine F, Chang CK, Sethakorn N, Das Gupta TK, Salti GI.

Biochem Biophys Res Commun. 2007 Mar 16;354(3):830-5. Epub 2007 Jan 23.

PMID:
17266927
14.

Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth.

Chaudhari A, Mahfouz M, Fialho AM, Yamada T, Granja AT, Zhu Y, Hashimoto W, Schlarb-Ridley B, Cho W, Das Gupta TK, Chakrabarty AM.

Biochemistry. 2007 Feb 20;46(7):1799-810. Epub 2007 Jan 24.

PMID:
17249693
15.

Clinical trials using chemopreventive vitamin D analogs in breast cancer.

Vijayakumar S, Boerner PS, Mehta RR, Packianathan S, Mehta RG, Das Gupta TK.

Cancer J. 2006 Nov-Dec;12(6):445-50. Review.

PMID:
17207311
16.

Bacterial proteins and CpG-rich extrachromosomal DNA in potential cancer therapy.

Mahfouz M, Hashimoto W, Das Gupta TK, Chakrabarty AM.

Plasmid. 2007 Jan;57(1):4-17. Epub 2006 Dec 12. Review.

PMID:
17166586
17.

Disrupting the entry barrier and attacking brain tumors: the role of the Neisseria H.8 epitope and the Laz protein.

Hong CS, Yamada T, Hashimoto W, Fialho AM, Das Gupta TK, Chakrabarty AM.

Cell Cycle. 2006 Aug;5(15):1633-41. Epub 2006 Aug 1.

PMID:
16861907
18.

Azurin, Plasmodium falciparum malaria and HIV/AIDS: inhibition of parasitic and viral growth by Azurin.

Chaudhari A, Fialho AM, Ratner D, Gupta P, Hong CS, Kahali S, Yamada T, Haldar K, Murphy S, Cho W, Chauhan VS, Das Gupta TK, Chakrabarty AM.

Cell Cycle. 2006 Aug;5(15):1642-8. Epub 2006 Aug 1.

PMID:
16861897
19.

Human cytochrome c enters murine J774 cells and causes G1 and G2/M cell cycle arrest and induction of apoptosis.

Hiraoka Y, Granja AT, Fialho AM, Schlarb-Ridley BG, Das Gupta TK, Chakrabarty AM, Yamada T.

Biochem Biophys Res Commun. 2005 Dec 16;338(2):1284-90. Epub 2005 Oct 24.

PMID:
16256942
20.

Resveratrol inhibits rhabdomyosarcoma cell proliferation.

Chow AW, Murillo G, Yu C, van Breemen RB, Boddie AW, Pezzuto JM, Das Gupta TK, Mehta RG.

Eur J Cancer Prev. 2005 Aug;14(4):351-6.

PMID:
16030425
21.

A novel RARbeta isoform directed by a distinct promoter P3 and mediated by retinoic acid in breast cancer cells.

Peng X, Maruo T, Cao Y, Punj V, Mehta R, Das Gupta TK, Christov K.

Cancer Res. 2004 Dec 15;64(24):8911-8.

22.

Rusticyanin, a bacterial electron transfer protein, causes G1 arrest in J774 and apoptosis in human cancer cells.

Yamada T, Hiraoka Y, Das Gupta TK, Chakrabarty AM.

Cell Cycle. 2004 Sep;3(9):1182-7. Epub 2004 Sep 1.

PMID:
15467448
23.

Regulation of mammalian cell growth and death by bacterial redox proteins: relevance to ecology and cancer therapy.

Yamada T, Hiraoka Y, Das Gupta TK, Chakrabarty AM.

Cell Cycle. 2004 Jun;3(6):752-5. Epub 2004 Jun 14. Review.

PMID:
15153808
24.

Modulation of mammalian cell growth and death by prokaryotic and eukaryotic cytochrome c.

Hiraoka Y, Yamada T, Goto M, Das Gupta TK, Chakrabarty AM.

Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6427-32. Epub 2004 Apr 13.

25.

Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin.

Yamada T, Hiraoka Y, Ikehata M, Kimbara K, Avner BS, Das Gupta TK, Chakrabarty AM.

Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4770-5. Epub 2004 Mar 24.

26.

Osteoblastic chondrosarcoma with cardiac and pulmonary arterial extension.

Kpodonu J, Massad MG, Anderson A, Das Gupta TK.

Eur J Cardiothorac Surg. 2004 Apr;25(4):650. No abstract available.

PMID:
15037290
27.

Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer.

Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, Yamada T, Constantinou AI, Christov K, White B, Li G, Majumdar D, Chakrabarty AM, Das Gupta TK.

Oncogene. 2004 Mar 25;23(13):2367-78.

PMID:
14981543
28.

Bacterial cupredoxin azurin and its interactions with the tumor suppressor protein p53.

Punj V, Das Gupta TK, Chakrabarty AM.

Biochem Biophys Res Commun. 2003 Dec 5;312(1):109-14. Review. No abstract available.

PMID:
14630027
29.

Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy.

Hussain EA, Mehta RR, Ray R, Das Gupta TK, Mehta RG.

Recent Results Cancer Res. 2003;164:393-411. Review.

PMID:
12899538
30.
31.
32.

Targeting colon cancer cells with genistein-17.1A immunoconjugate.

Gentile MS, Vasu C, Green A, Murillo G, Das Gupta TK, Constantinou AI, Prabhakar BS, Salti GI.

Int J Oncol. 2003 May;22(5):955-9.

PMID:
12684659
33.

Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D.

Mehta RG, Hussain EA, Mehta RR, Das Gupta TK.

Mutat Res. 2003 Feb-Mar;523-524:253-64.

PMID:
12628523
34.

The bacterial redox protein azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppressor protein p53.

Yamada T, Goto M, Punj V, Zaborina O, Kimbara K, Das Gupta TK, Chakrabarty AM.

Infect Immun. 2002 Dec;70(12):7054-62.

35.

Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.

Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, Majumdar D, Cunningham E, Das Gupta TK, Chakrabarty AM.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14098-103. Epub 2002 Oct 22.

36.

Clinical node-negative thick melanoma.

Salti GI, Kansagra A, Warso MA, Ronan SG, Das Gupta TK.

Arch Surg. 2002 Mar;137(3):291-5.

PMID:
11888451
37.

In vitro transformation of human congenital naevus to malignant melanoma.

Mehta RR, Bratescu L, Graves JM, Shilkaitis A, Green A, Mehta RG, Das Gupta TK.

Melanoma Res. 2002 Feb;12(1):27-33.

PMID:
11828255
38.

Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent.

Salti GI, Kichina JV, Das Gupta TK, Uddin S, Bratescu L, Pezzuto JM, Mehta RG, Constantinou AI.

Melanoma Res. 2001 Apr;11(2):99-104.

PMID:
11333133
39.

A novel use for the comet assay: detection of topoisomerase II inhibitors.

Salti GI, Das Gupta TK, Constantinou AI.

Anticancer Res. 2000 Sep-Oct;20(5A):3189-93.

PMID:
11062742
40.

Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.

Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK.

Cancer Res. 2000 Sep 15;60(18):5012-6.

41.
42.

Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells.

Salti GI, Grewal S, Mehta RR, Das Gupta TK, Boddie AW Jr, Constantinou AI.

Eur J Cancer. 2000 Apr;36(6):796-802.

PMID:
10762754
43.

Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors.

Lazzaro G, Agadir A, Qing W, Poria M, Mehta RR, Moriarty RM, Das Gupta TK, Zhang XK, Mehta RG.

Eur J Cancer. 2000 Apr;36(6):780-6.

PMID:
10762752
44.

Determination of betulinic acid in mouse blood, tumor and tissue homogenates by liquid chromatography-electrospray mass spectrometry.

Shin YG, Cho KH, Chung SM, Graham J, Das Gupta TK, Pezzuto JM.

J Chromatogr B Biomed Sci Appl. 1999 Sep 24;732(2):331-6.

PMID:
10517355
45.

Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma.

Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK.

Cancer. 1999 Jan 15;85(2):375-82.

PMID:
10023705
46.

Molecular analysis of 1p36 breakpoints in two Merkel cell carcinomas.

Van Gele M, Van Roy N, Ronan SG, Messiaen L, Vandesompele J, Geerts ML, Naeyaert JM, Blennow E, Bar-Am I, Das Gupta TK, van der Drift P, Versteeg R, Leonard JH, Speleman F.

Genes Chromosomes Cancer. 1998 Sep;23(1):67-71.

PMID:
9713999
47.

Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.

Mehta RR, McDermott JH, Hieken TJ, Marler KC, Patel MK, Wild LD, Das Gupta TK.

J Clin Oncol. 1998 Jul;16(7):2409-16.

PMID:
9667258
48.

Surgery for metastatic melanoma.

Sharpless SM, Das Gupta TK.

Semin Surg Oncol. 1998 Jun;14(4):311-8. Review.

PMID:
9588724
49.

Development of a new metastatic human breast carcinoma xenograft line.

Mehta RR, Graves JM, Shilkaitis A, Das Gupta TK.

Br J Cancer. 1998 Feb;77(4):595-604.

50.

Evaluation of newer prognostic markers for adult soft tissue sarcomas.

Levine EA, Holzmayer T, Bacus S, Mechetner E, Mera R, Bolliger C, Roninson IB, Das Gupta TK.

J Clin Oncol. 1997 Oct;15(10):3249-57.

PMID:
9336362

Supplemental Content

Loading ...
Support Center